Review



αcd11b  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Miltenyi Biotec αcd11b
    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.
    αcd11b, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 233 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/CD11b+Antibody%2C+anti-mouse%2C+REAfinity/bio_rxiv__64898__2026__03__20__712678-209-26-27
    Average 95 stars, based on 233 article reviews
    αcd11b - by Bioz Stars, 2026-10
    95/100 stars

    Images

    1) Product Images from "TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma"

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

    Journal: bioRxiv

    doi: 10.64898/2026.03.20.712678

    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.
    Figure Legend Snippet: Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.

    Techniques Used: Flow Cytometry, RNA Sequencing, Derivative Assay, Comparison, Staining, MANN-WHITNEY

    Analysis of splenocytes from premalignant (day 50) EµMyc and EµMyc Tet2 −/− mice. (A) Spleen to body weight ratio for each mouse and (B) absolute splenocyte counts (*10 7 ) ( EµMyc : n=35, EµMyc Tet2 −/− : n=26). (C) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and B cells (B220 + CD19 + ) ( EµMyc : n=18, EµMyc Tet2 −/− : n=13). (D) Splenic B cell subsets were assessed via flow cytometry: IgM − progenitors (B220 + CD19 + IgM − IgD − ), IgM + IgD − immature-(like) (B220 + CD19 + IgM + IgD − ), and IgM + IgD + mature (B220 + CD19 + IgM + IgD + ) B cells. The upper panel summarizes all data ( wildtype : n=10, Tet2 −/− : n=11, EµMyc : n=18, EµMyc Tet2 −/− : n=13), the lower panel shows representative dot blots for the IgM/IgD gate. (E) Volcano plots display RNA-seq-derived transcriptional profiles of premalignant FACS-sorted splenic IgM − progenitors (left; B220 + CD19 + IgM − IgD − ) and IgM + immature(-like) (right; B220 + CD19 + IgM + IgD − ) B cells. Comparisons between EµMyc Tet2 −/− (n=5) and EµMyc (n=6) mice were performed separately for each cell type. Axis ranges were kept identical across volcano plots to allow direct comparison. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red. Bar plots show median with interquartile range. Statistical significance was determined using (A) unpaired t-test or (B, C) Mann-Whitney test and (D) two-way ANOVA, with Holm-Šidák correction for multiple comparisons. Normality was assessed using the Shapiro-Wilk test. n.d. = not detected, ns = not significant, *p<0.05, **p<0.005, ***p<0.0005.
    Figure Legend Snippet: Analysis of splenocytes from premalignant (day 50) EµMyc and EµMyc Tet2 −/− mice. (A) Spleen to body weight ratio for each mouse and (B) absolute splenocyte counts (*10 7 ) ( EµMyc : n=35, EµMyc Tet2 −/− : n=26). (C) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and B cells (B220 + CD19 + ) ( EµMyc : n=18, EµMyc Tet2 −/− : n=13). (D) Splenic B cell subsets were assessed via flow cytometry: IgM − progenitors (B220 + CD19 + IgM − IgD − ), IgM + IgD − immature-(like) (B220 + CD19 + IgM + IgD − ), and IgM + IgD + mature (B220 + CD19 + IgM + IgD + ) B cells. The upper panel summarizes all data ( wildtype : n=10, Tet2 −/− : n=11, EµMyc : n=18, EµMyc Tet2 −/− : n=13), the lower panel shows representative dot blots for the IgM/IgD gate. (E) Volcano plots display RNA-seq-derived transcriptional profiles of premalignant FACS-sorted splenic IgM − progenitors (left; B220 + CD19 + IgM − IgD − ) and IgM + immature(-like) (right; B220 + CD19 + IgM + IgD − ) B cells. Comparisons between EµMyc Tet2 −/− (n=5) and EµMyc (n=6) mice were performed separately for each cell type. Axis ranges were kept identical across volcano plots to allow direct comparison. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red. Bar plots show median with interquartile range. Statistical significance was determined using (A) unpaired t-test or (B, C) Mann-Whitney test and (D) two-way ANOVA, with Holm-Šidák correction for multiple comparisons. Normality was assessed using the Shapiro-Wilk test. n.d. = not detected, ns = not significant, *p<0.05, **p<0.005, ***p<0.0005.

    Techniques Used: Flow Cytometry, RNA Sequencing, Derivative Assay, Comparison, MANN-WHITNEY

    Related Articles

    Labeling:

    Article Title: Inhibition of glial D-serine release rescues synaptic damage after brain injury.
    Article Snippet: To measure cell viability, single cell suspensions were incubated for 1 h at 4 C with Ghost Violet 540 viability dye (#13-0879-T100, Tonbo Biosciences, San Diego, CA). .. Cells were then labeled with αACSA-2 (1:50; #130-116-141, Miltenyi Biotech), αCD11b (1:50; #130-113-802, Miltenyi Biotech), and αCD45 (1:100; #103114, Biolegend, San Diego, CA) for 30 min at 4 C. Samples were sorted on a MoFlo Astrios Cell Sorter (Beckman Coulter, Brea, CA) into PBS for HPLC, centrifuged (5000 g for 10 min), resuspended in 6% Trichloroacetic acid, and frozen at 80 C and shipped on dry ice for HPLC analysis. ..

    Article Title: Inhibition of glial D‐serine release rescues synaptic damage after brain injury
    Article Snippet: To measure cell viability, single cell suspensions were incubated for 1 h at 4°C with Ghost Violet 540 viability dye (#13‐0879‐T100, Tonbo Biosciences, San Diego, CA). .. Cells were then labeled with αACSA‐2 (1:50; #130‐116‐141, Miltenyi Biotech), αCD11b (1:50; #130‐113‐802, Miltenyi Biotech), and αCD45 (1:100; #103114, Biolegend, San Diego, CA) for 30 min at 4°C. .. Samples were sorted on a MoFlo Astrios Cell Sorter (Beckman Coulter, Brea, CA) into PBS for HPLC, centrifuged (5000× g for 10 min), resuspended in 6% Trichloroacetic acid, and frozen at −80°C and shipped on dry ice for HPLC analysis.

    High Performance Liquid Chromatography:

    Article Title: Inhibition of glial D-serine release rescues synaptic damage after brain injury.
    Article Snippet: To measure cell viability, single cell suspensions were incubated for 1 h at 4 C with Ghost Violet 540 viability dye (#13-0879-T100, Tonbo Biosciences, San Diego, CA). .. Cells were then labeled with αACSA-2 (1:50; #130-116-141, Miltenyi Biotech), αCD11b (1:50; #130-113-802, Miltenyi Biotech), and αCD45 (1:100; #103114, Biolegend, San Diego, CA) for 30 min at 4 C. Samples were sorted on a MoFlo Astrios Cell Sorter (Beckman Coulter, Brea, CA) into PBS for HPLC, centrifuged (5000 g for 10 min), resuspended in 6% Trichloroacetic acid, and frozen at 80 C and shipped on dry ice for HPLC analysis. ..

    FACS:

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma
    Article Snippet: B cells were enriched from splenic cell suspensions using MagniSort TM Streptavidin Negative Selection Beads (ThermoFisher, MSNB-6002-74), according to the manufactureŕs instruction. .. For depletion of non-B cells, 300 μl of a biotinylated antibody mix (diluted 1:100 in FACS-B) containing αCD4 (Biolegend, 100404), αCD8 (Biolegend, 100704), αNK1.1 (Biolegend, 108704), αCD11b (Milteny Biotec, 130-113-242), αGr1 (Biolegend, 108404) and αTer119 (Biolegend, 116204) was used. ..



    Similar Products

    αcd11b  (Miltenyi Biotec)
    95
    Miltenyi Biotec αcd11b
    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.
    αcd11b, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/CD11b+Antibody%2C+anti-mouse%2C+REAfinity/bio_rxiv__64898__2026__03__20__712678-209-26-27
    Average 95 stars, based on 1 article reviews
    αcd11b - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    αcd11b  (Thermo Fisher)
    90
    Thermo Fisher αcd11b
    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.
    αcd11b, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/pm37683186-256-9-15
    Average 90 stars, based on 1 article reviews
    αcd11b - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    cd11b antibody, anti-mouse, reafinity  (Miltenyi Biotec)
    95
    Miltenyi Biotec cd11b antibody, anti-mouse, reafinity
    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.
    Cd11b Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/CD11b+Antibody%2C+anti-mouse%2C+REAfinity/custom%40130-113-805%4040711876
    Average 95 stars, based on 1 article reviews
    cd11b antibody, anti-mouse, reafinity - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    αcd11b m1/70  (Thermo Fisher)
    90
    Thermo Fisher αcd11b m1/70

    αcd11b M1/70, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/anti+cd11b/pmc11480410-5-1-3
    Average 90 stars, based on 1 article reviews
    αcd11b m1/70 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    αcd11b  (Becton Dickinson)
    90
    Becton Dickinson αcd11b

    αcd11b, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/%CE%B1cd11b+antibody/pm37356205-80-19-23
    Average 90 stars, based on 1 article reviews
    αcd11b - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    αcd11b-bv421  (Becton Dickinson)
    90
    Becton Dickinson αcd11b-bv421

    αcd11b Bv421, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/cd25+bv421+antibody/us11369668-1417-30-31
    Average 90 stars, based on 1 article reviews
    αcd11b-bv421 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    αcd11b (748700)  (Becton Dickinson)
    90
    Becton Dickinson αcd11b (748700)

    αcd11b (748700), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B1cd11b/%CE%B1cd11b+antibody/pmc09099860-199-5-17
    Average 90 stars, based on 1 article reviews
    αcd11b (748700) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.

    Journal: bioRxiv

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

    doi: 10.64898/2026.03.20.712678

    Figure Lengend Snippet: Kaplan-Meier survival analysis displaying (A) overall survival probability, and (B) median time to death in days for all malignant mice ( EµMyc : n=27, EµMyc Tet2 +/− : n=44, EµMyc Tet2 −/− : n=27). (C) Spleen to body weight ratio in non-malignant (280-320 days) mice ( wildtype : n=7 , Tet2 +/− : n=13 , Tet2 −/− : n=6) and malignant mice, excluding animals without overt disease at 300 days ( EµMyc : n=13, EµMyc Tet2 +/− : n=11, EµMyc Tet2 −/− : n=23). (D) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and malignant B cells (B220 + CD19 + ) ( EµMyc : n=10, EµMyc Tet2 −/− : n=12). (E) Lymphoma immunophenotype in the spleen. Mixed tumors were defined as tumors where neither IgM − nor IgM + cells constituted >80% of the total tumor population. (F) Volcano plots displaying RNA-seq-derived transcriptional profiles of FACS-sorted IgM − tumor (left; B220 + CD19 + IgM − IgD − ) and IgM + tumor (right; B220 + CD19 + IgM + IgD − ) cells. Comparison between EµMyc Tet2 −/− and EµMyc (IgM − tumors: n=4 vs. n=5, IgM + tumors: n=4 vs. n=3) mice was performed separately for each cell type. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− tumors are shown in blue; upregulated genes are shown in red. (G) DNA content and (H) polyploid cell fraction of splenic lymphoma cells, assessed by TO-PRO-3 staining via flow cytometry ( EµMyc : n=7, EµMyc Tet2 −/− : n=8). Flow cytometry assessment of (I) DNA double strand breaks by γH2AX staining ( EµMyc : n=6, EµMyc Tet2 −/− : n=7) and (J) apoptosis by cleaved Caspase-3 staining ( EµMyc : n=5, EµMyc Tet2 −/− : n=5) within splenic lymphoma cells. Bar graphs show median with interquartile range. Statistical significance was determined using (A) Mantel-Cox test, (B, C) one-way ANOVA, (D, G) Mann-Whitney test, or (H, I, J) unpaired t-test, depending on normality (Shapiro-Wilk test) with Holm-Šidák correction for multiple comparisons. ns = not significant, *p<0.05, **p<0.005.

    Article Snippet: For depletion of non-B cells, 300 μl of a biotinylated antibody mix (diluted 1:100 in FACS-B) containing αCD4 (Biolegend, 100404), αCD8 (Biolegend, 100704), αNK1.1 (Biolegend, 108704), αCD11b (Milteny Biotec, 130-113-242), αGr1 (Biolegend, 108404) and αTer119 (Biolegend, 116204) was used.

    Techniques: Flow Cytometry, RNA Sequencing, Derivative Assay, Comparison, Staining, MANN-WHITNEY

    Analysis of splenocytes from premalignant (day 50) EµMyc and EµMyc Tet2 −/− mice. (A) Spleen to body weight ratio for each mouse and (B) absolute splenocyte counts (*10 7 ) ( EµMyc : n=35, EµMyc Tet2 −/− : n=26). (C) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and B cells (B220 + CD19 + ) ( EµMyc : n=18, EµMyc Tet2 −/− : n=13). (D) Splenic B cell subsets were assessed via flow cytometry: IgM − progenitors (B220 + CD19 + IgM − IgD − ), IgM + IgD − immature-(like) (B220 + CD19 + IgM + IgD − ), and IgM + IgD + mature (B220 + CD19 + IgM + IgD + ) B cells. The upper panel summarizes all data ( wildtype : n=10, Tet2 −/− : n=11, EµMyc : n=18, EµMyc Tet2 −/− : n=13), the lower panel shows representative dot blots for the IgM/IgD gate. (E) Volcano plots display RNA-seq-derived transcriptional profiles of premalignant FACS-sorted splenic IgM − progenitors (left; B220 + CD19 + IgM − IgD − ) and IgM + immature(-like) (right; B220 + CD19 + IgM + IgD − ) B cells. Comparisons between EµMyc Tet2 −/− (n=5) and EµMyc (n=6) mice were performed separately for each cell type. Axis ranges were kept identical across volcano plots to allow direct comparison. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red. Bar plots show median with interquartile range. Statistical significance was determined using (A) unpaired t-test or (B, C) Mann-Whitney test and (D) two-way ANOVA, with Holm-Šidák correction for multiple comparisons. Normality was assessed using the Shapiro-Wilk test. n.d. = not detected, ns = not significant, *p<0.05, **p<0.005, ***p<0.0005.

    Journal: bioRxiv

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

    doi: 10.64898/2026.03.20.712678

    Figure Lengend Snippet: Analysis of splenocytes from premalignant (day 50) EµMyc and EµMyc Tet2 −/− mice. (A) Spleen to body weight ratio for each mouse and (B) absolute splenocyte counts (*10 7 ) ( EµMyc : n=35, EµMyc Tet2 −/− : n=26). (C) Splenic immune cell composition assessed by flow cytometry: monocytes/macrophages (CD11b + Gr1 − ), granulocytes (CD11b + Gr1 + ), erythroid progenitors (nucleated Ter119 + ), NK cells (TCRβ − NK1.1 + ), CD4 + T cells (TCRβ + CD4 + ), CD8 + T cells (TCRβ + CD8 + ), and B cells (B220 + CD19 + ) ( EµMyc : n=18, EµMyc Tet2 −/− : n=13). (D) Splenic B cell subsets were assessed via flow cytometry: IgM − progenitors (B220 + CD19 + IgM − IgD − ), IgM + IgD − immature-(like) (B220 + CD19 + IgM + IgD − ), and IgM + IgD + mature (B220 + CD19 + IgM + IgD + ) B cells. The upper panel summarizes all data ( wildtype : n=10, Tet2 −/− : n=11, EµMyc : n=18, EµMyc Tet2 −/− : n=13), the lower panel shows representative dot blots for the IgM/IgD gate. (E) Volcano plots display RNA-seq-derived transcriptional profiles of premalignant FACS-sorted splenic IgM − progenitors (left; B220 + CD19 + IgM − IgD − ) and IgM + immature(-like) (right; B220 + CD19 + IgM + IgD − ) B cells. Comparisons between EµMyc Tet2 −/− (n=5) and EµMyc (n=6) mice were performed separately for each cell type. Axis ranges were kept identical across volcano plots to allow direct comparison. Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>1. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red. Bar plots show median with interquartile range. Statistical significance was determined using (A) unpaired t-test or (B, C) Mann-Whitney test and (D) two-way ANOVA, with Holm-Šidák correction for multiple comparisons. Normality was assessed using the Shapiro-Wilk test. n.d. = not detected, ns = not significant, *p<0.05, **p<0.005, ***p<0.0005.

    Article Snippet: For depletion of non-B cells, 300 μl of a biotinylated antibody mix (diluted 1:100 in FACS-B) containing αCD4 (Biolegend, 100404), αCD8 (Biolegend, 100704), αNK1.1 (Biolegend, 108704), αCD11b (Milteny Biotec, 130-113-242), αGr1 (Biolegend, 108404) and αTer119 (Biolegend, 116204) was used.

    Techniques: Flow Cytometry, RNA Sequencing, Derivative Assay, Comparison, MANN-WHITNEY

    Journal: Nature Communications

    Article Title: Centrioles are frequently amplified in early B cell development but dispensable for humoral immunity

    doi: 10.1038/s41467-024-53222-4

    Figure Lengend Snippet:

    Article Snippet: , αCD11b , eBioscience , 17-0112-83 , M1/70 , 1:200.

    Techniques: